Home › Opioid Overdose › NCT07631598

Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

Buprenorphine Implementation at Syringe Services Programs To Reduce Overdoses: A Type 1 Hybrid Effectiveness-Implementation Trial

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

1. ≥ 18 years old;
2. Meet DSM-5 criteria for moderate or severe OUD;
3. Interest in receiving buprenorphine treatment;
4. Speaks English or Spanish;
5. Currently an SSP client at the time of enrollment;
6. Ability to provide informed consent.

Exclusion Criteria:

1. Current use of prescribed opioid agonist treatment, as assessed by self-report, at the time of enrollment;
2. Unstable mental health or medical condition that requires an immediate clinical evaluation or higher level of care;
3. Allergy to buprenorphine;
4. Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law. or have pending legal action that could prevent participation on study activities.

About the study

This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms.

The study compares two ways of connecting people to treatment:

Referral to a community treatment provider (usual care before the new program begins).

Onsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider.

Participants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after the new program begins to see how it affects treatment engagement and health outcomes.

The study will also examine how easy or difficult it is for SSPs to start and run the new program, how acceptable it is to staff and participants, and whether it is cost-effective.

The overall goal is to find better ways to expand access to life-saving opioid treatment in community-based settings.

What is being tested

• Standard of Care Referral (other)
• Low Threshold Buprenorphine (behavioral)

Sponsor: Montefiore Medical Center · Participants: 512 · Started: Aug 17, 2026

Contact the study team

• Megan M Ghiroli · Phone: 12036068136
• Aaron D Fox, MD, MS · Phone: 718-920-7173

Official record on ClinicalTrials.gov — NCT07631598

Locations in the U.S.

Conditions

• Opioid Overdose
• Follicular Lymphoma

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.